ALIGOS THERAPEUTICS INC's ticker is ALGS and the CUSIP is 01626L105. A total of 41 filers reported holding ALIGOS THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $289 | -55.1% | 829,485 | +26.1% | 0.00% | -50.0% |
| Q1 2024 | $644 | +74.1% | 657,995 | +17.6% | 0.00% | +100.0% |
| Q4 2023 | $370 | -11.9% | 559,367 | -0.9% | 0.00% | -50.0% |
| Q3 2023 | $420 | -23.2% | 564,715 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $547 | +11.2% | 564,715 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $492 | +54.7% | 564,715 | +68.7% | 0.00% | 0.0% |
| Q4 2022 | $318 | -99.9% | 334,704 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $366,000 | -3.7% | 334,704 | +6.5% | 0.00% | 0.0% |
| Q2 2022 | $380,000 | +0.8% | 314,334 | +78.9% | 0.00% | 0.0% |
| Q1 2022 | $377,000 | – | 175,721 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 1,457,937 | $510,278 | 0.66% |
| Pivotal bioVenture Partners Investment Advisor LLC | 743,215 | $260,125 | 0.20% |
| Vivo Capital, LLC | 3,547,030 | $1,241,461 | 0.12% |
| Opaleye Management Inc. | 1,260,000 | $441,000 | 0.10% |
| EcoR1 Capital, LLC | 6,389,468 | $2,236,314 | 0.07% |
| Deep Track Capital, LP | 6,102,770 | $2,135,970 | 0.06% |
| TANG CAPITAL MANAGEMENT LLC | 1,650,000 | $577,500 | 0.06% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 655,515 | $229,430 | 0.05% |
| Newtyn Management, LLC | 719,287 | $251,750 | 0.05% |
| ARMISTICE CAPITAL, LLC | 7,256,410 | $2,539,744 | 0.03% |